Quick Takeaways
- Longitude Capital Partners V, LLC filed SCHEDULE 13G for CytomX Therapeutics, Inc. Common Stock, $0.00001 par value per share (CTMX).
- Disclosed ownership: 7.3%.
- Date of event: 13 May 2025.
Quoteable Key Fact
"Longitude Capital Partners V, LLC disclosed 7.3% ownership in CytomX Therapeutics, Inc. Common Stock, $0.00001 par value per share (CTMX) on 13 May 2025."
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Longitude Capital Partners V, LLC | 7.3% | 11,538,461 | 0 | 11,538,461 | /s/ Cristiana Blauth Oliveira | Cristiana Blauth Oliveira, Authorized Signatory | |
| Longitude Venture Partners V, L.P. | 7.3% | 11,538,461 | 0 | 11,538,461 | /s/ Cristiana Blauth Oliveira | Cristiana Blauth Oliveira, Authorized Signatory | |
| Patrick G. Enright | 7.3% | 11,538,461 | 0 | 11,538,461 | /s/ Cristiana Blauth Oliveira | Cristiana Blauth Oliveira, as attorney-in-fact for Patrick G. Enright | |
| Juliet Tammenoms Bakker | 7.3% | 11,538,461 | 0 | 11,538,461 | /s/ Cristiana Blauth Oliveira | Cristiana Blauth Oliveira, as attorney-in-fact for Juliet Tammenoms Bakker |